Oncimmune Holdings plc, an early cancer detection technology company, saw its shares start trading on London’s AIM market today.  Oncimmune raised GBP11.0 million through the issue of shares at 130.00 pence per share. Its market capitalisation upon admission was around GBP66.3 million.

Oncimmune intends to use proceeds from the float to continue to develop its products, focused on auto-antibody tests which it said have the potential to detect cancer up to four years earlier than other methods, and can be applied to a “very wide range” of solid tumour types.  Mackintosh Capital’s partners have been investors in Oncimmune since 2012.

For more details, visit http://www.londonstockexchange.com/exchange/news/market-news/market-news-detail/ONC/12819829.html